Skip to main content
CDT
NASDAQ Life Sciences

CDT Equity Expands ATM Offering to $76M, Authorizing Massive Potential Dilution

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
9
Price
$3.8
Mkt Cap
$24.084M
52W Low
$3.83
52W High
$4,200
Market data snapshot near publication time

summarizeSummary

CDT Equity Inc. has significantly expanded its At-The-Market (ATM) equity offering program, increasing the potential sale of common stock from $3.5 million to over $76 million, representing a substantial potential dilution.


check_boxKey Events

  • ATM Program Dramatically Expanded

    The company increased the aggregate amount of common stock that may be offered and sold under its At-The-Market (ATM) program from $3,556,586 to $76,077,218.

  • Significant Potential Dilution

    The new authorization allows for the sale of shares representing over 300% of the company's current market capitalization, indicating a substantial potential dilution for existing shareholders.

  • Enabled by Public Float Increase

    The expansion was made possible because the company's public float exceeded $75.0 million as of March 24, 2026, removing previous limitations under Form S-3. This follows a recent reverse stock split.

  • Amendment to Existing Program

    This is Amendment No. 6 to a prospectus supplement, updating an existing Sales Agreement dated October 23, 2024, with A.G.P./Alliance Global Partners.


auto_awesomeAnalysis

This filing reveals a dramatic increase in CDT Equity Inc.'s At-The-Market (ATM) equity offering program, raising the authorized amount from approximately $3.5 million to over $76 million. This expansion, enabled by the company's public float exceeding $75 million, allows the company to sell shares equivalent to more than three times its current market capitalization. While it provides a significant capital raising facility, the potential for such extensive dilution is highly negative for existing shareholders, especially given the stock is trading near its 52-week low. This move suggests a critical need for capital and will likely exert substantial downward pressure on the stock price as shares are sold into the market. This follows a recent 1-for-25 reverse stock split on March 26, 2026, which likely contributed to the public float increase, enabling this larger offering.

At the time of this filing, CDT was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $3.83 to $4,200.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CDT - Latest Insights

CDT
Apr 21, 2026, 9:56 PM EDT
Filing Type: S-3
Importance Score:
9
CDT
Apr 15, 2026, 5:01 PM EDT
Filing Type: 10-K
Importance Score:
9
CDT
Apr 02, 2026, 4:15 PM EDT
Filing Type: 424B5
Importance Score:
9
CDT
Mar 30, 2026, 9:21 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
CDT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CDT
Mar 25, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
CDT
Mar 18, 2026, 4:53 PM EDT
Filing Type: 8-K
Importance Score:
9
CDT
Mar 18, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
CDT
Mar 09, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
CDT
Mar 06, 2026, 4:12 PM EST
Filing Type: DEF 14A
Importance Score:
10